David Melnick
2019
In 2019, David Melnick earned a total compensation of $936.3K as Chief Medical Officer at Spero Therapeutics, a 43% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $156,000 |
|---|---|
| Option Awards | $271,837 |
| Salary | $389,167 |
| Stock Awards | $118,493 |
| Other | $792 |
| Total | $936,288 |
Melnick received $389.2K in salary, accounting for 42% of the total pay in 2019.
Melnick also received $156K in non-equity incentive plan, $271.8K in option awards, $118.5K in stock awards and $792 in other compensation.
Rankings
In 2019, David Melnick's compensation ranked 9,575th out of 13,971 executives tracked by ExecPay. In other words, Melnick earned more than 31.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,575 out of 13,971 | 32nd |
Division Manufacturing | 3,851 out of 5,701 | 33rd |
Major group Chemicals And Allied Products | 1,464 out of 2,200 | 34th |
Industry group Drugs | 1,251 out of 1,886 | 34th |
Industry Pharmaceutical Preparations | 929 out of 1,398 | 34th |
Source: SEC filing on September 30, 2020.
Melnick's colleagues
We found two more compensation records of executives who worked with David Melnick at Spero Therapeutics in 2019.